Beyond Medical Technologies Inc. is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. . Products Now Available at Walmart Micron Technologies' three-ply medical grade face masks and N95 medical grade face masks have been approved for sale by Walmart. Micron Technologies has completed the onboarding process and its products will be available at by the ...

Beyond Medical Technologies Inc. (" Beyond Medical " or the " Company ") (CSE: DOCT) ( Frankfurt : 7FM4) is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. (" Micron Technologies ").

Products Now Available at Walmart

Micron Technologies' three-ply medical grade face masks and N95 medical grade face masks have been approved for sale by Walmart. Micron Technologies has completed the onboarding process and its products will be available at www.walmart.com by the beginning of April 2021 .

Kal Malhi , CEO of Beyond Medical states: "We are pleased to offer our products to loyal Walmart customers at competitive prices. The availability of our product with one of the largest retailers in the world will bring significant exposure to our made-in- Canada medical face mask brand.  Our recently completed capital raise will allow us to ramp up manufacturing to meet new demand from Walmart customers."

In addition to Walmart, Micron Technologies' products are also available on Amazon and Shopify. Institutional customers and those who are interested in obtaining a quote for large size orders are encouraged to contact Milan@micronti.com .

Three-Ply Medical Grade Face Masks

Micron Technologies has been manufacturing and selling three-ply medical grade face masks since August 2020 . The masks are available in the colour blue and black. The majority of Micron Technologies' sales have been to provincial governments; however, sales are also being completed online to various other customers. Micron Technologies is considering acquiring additional manufacturing equipment and hiring more personnel as it is currently operating at full capacity and continues to sell out of inventory.

N95 Face Masks

In addition to the three-ply medical grade face masks, Micron Technologies is also manufacturing N95 Model 8800 face masks. Micron Technologies' N95 Model 8800 face masks have been approved by Health Canada and the US Food and Drug Administration. Additionally, the N95 Model 8800 face masks have passed testing with Kinetrics Analytical and Environmental Laboratories. Accordingly, Micron Technologies is confident that its N95 Model 8800 face masks will obtain medical-grade certification from the National Institute for Occupational Safety and Health in the coming weeks.  There are currently a limited number of NIOSH approved medical face mask manufacturers and the demand for these masks in outpacing supply.

On February 2,2012 , Washington Post reported on N95 masks: "The initial shortage has eased, but there still aren't enough medical masks for health-care workers, let alone others. Demand for N95s is 500 to 1,000 percent higher than it was a year ago, said Megan Ranney , co-founder of Get Us PPE, which helps front-line workers obtain personal protective equipment."

Last month President Biden's chief medical advisor for Covid-19, Dr. Anthony Fauci , indicated that Americans may still be wearing masks in 2023, as mask-wearing has been critical in slowing down the spread Covid-19. N95 masks are the gold standard of personal protective equipment, particularly among healthcare professionals as they provide the highest level of protection for the user and those in close proximity. Beyond Medical hopes to have its N95 Model 8800 face masks certified as soon as possible in an effort to reduce the spread of Covid-19.

About Beyond Medical

Beyond Medical is an industrial/technology company with a manufacturing facility located in Delta, BC . The Company is developing its Organivore and Pharmavore waste digesters using its proprietary technology. The Company, through its subsidiary Micron Technologies, is also manufacturing medical grade face masks.

The Company is not making any express or implied claims that its products have the ability to eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release. The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

FORWARD LOOKING STATEMENTS:

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

SOURCE Beyond Medical Technologies Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2021/30/c9088.html

News Provided by Canada Newswire via QuoteMedia

Gilead's Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS

ASCENT Subgroup Analysis Provides Insights on Treatment Outcomes for Black Patients with Metastatic TNBC –

Separate ASCENT Post Hoc Analysis Examines Outcomes in Patients Who Discontinue Treatment Due to Progressive Disease

Keep reading... Show less

Aptose to Hold Corporate Update Monday, December 13th

HM43239 clinical update in AML after oral presentation at 2021 ASH Annual Meeting
Luxeptinib clinical update in AML and B-cell cancers

Aptose Biosciences Inc. ("Aptose") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update on Monday, December 13, 2021 at 5:30 PM ET, in conjunction with participation at the 2021 ASH Annual Meeting. The event will include a review of HM43239 data highlighted in an oral presentation at ASH, as well as the up-to-date clinical status of luxeptinib. HM43239 is an oral, myeloid kinome inhibitor in an international Phase 12 trial in patients with relapsed or refractory acute myeloid leukemia (AML). Luxeptinib is an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 ab trial in patients with relapsed or refractory B cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 ab trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS)

Keep reading... Show less

Bristol Myers Squibb's Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency

Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla ® (apremilast) and placebo in treating adults with moderate to severe plaque psoriasis

U.S. Food and Drug Administration assigned a target action date of September 10, 2022; European Medicines Agency validation confirms the submission is complete and begins the centralized review process

Keep reading... Show less

INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, CTXS, OWLT, PTON Investors, Lead Plaintiff Deadlines Set

Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://www.ksfcounsel.com/cases/nyse-bmy/

Keep reading... Show less

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, LSPD INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits

Bristol-Myers Squibb Company (NYSE:BMY)

Keep reading... Show less
8,000 plus Attend Boosh Sponsored Planted Expo in Vancouver

8,000 plus Attend Boosh Sponsored Planted Expo in Vancouver

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the "Company") is proud to announce that over 8,000 consumers and investors visited the largest plant-based expo in Canada; Planted-Expo at which Boosh was the presenting sponsor. At the event Boosh proudly introduced its brand-new shelf stable line of Boosh Mac & Cheeze; Nacho and Better Cheddar to rave reviews, and provided samples to consumers of Boosh's favourite foods including Shephard's Pie, and recently acquired brands such as Salt Spring Harvest pate and Pulse Specialty Kitchen plant-based cheeses.

Keep reading... Show less

Top News

Related News